SELLAS Life Sciences Group (SLS) Competitors $1.17 -0.05 (-4.10%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SLS vs. NEOS, CORV, KMDA, BTMD, QTTB, JSPR, ACIU, CYRX, DSGN, and KODShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Neos Therapeutics (NEOS), Correvio Pharma (CORV), Kamada (KMDA), biote (BTMD), Q32 Bio (QTTB), Jasper Therapeutics (JSPR), AC Immune (ACIU), Cryoport (CYRX), Design Therapeutics (DSGN), and Kodiak Sciences (KOD). SELLAS Life Sciences Group vs. Neos Therapeutics Correvio Pharma Kamada biote Q32 Bio Jasper Therapeutics AC Immune Cryoport Design Therapeutics Kodiak Sciences Neos Therapeutics (NASDAQ:NEOS) and SELLAS Life Sciences Group (NASDAQ:SLS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, institutional ownership, earnings and analyst recommendations. Does the media prefer NEOS or SLS? In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Neos Therapeutics. MarketBeat recorded 1 mentions for SELLAS Life Sciences Group and 0 mentions for Neos Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 1.19 beat Neos Therapeutics' score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the news media. Company Overall Sentiment Neos Therapeutics Neutral SELLAS Life Sciences Group Positive Which has stronger earnings & valuation, NEOS or SLS? Neos Therapeutics has higher revenue and earnings than SELLAS Life Sciences Group. Neos Therapeutics is trading at a lower price-to-earnings ratio than SELLAS Life Sciences Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeos Therapeutics$64.65M0.89-$16.90M-$0.34-3.38SELLAS Life Sciences Group$1M82.34-$37.34M-$0.69-1.70 Is NEOS or SLS more profitable? SELLAS Life Sciences Group has a net margin of 0.00% compared to Neos Therapeutics' net margin of -38.35%. Neos Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets Neos Therapeutics-38.35% N/A -28.46% SELLAS Life Sciences Group N/A -629.46%-178.65% Do insiders and institutionals believe in NEOS or SLS? 33.1% of Neos Therapeutics shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 3.8% of Neos Therapeutics shares are owned by insiders. Comparatively, 1.2% of SELLAS Life Sciences Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, NEOS or SLS? Neos Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, SELLAS Life Sciences Group has a beta of 2.39, indicating that its share price is 139% more volatile than the S&P 500. Does the MarketBeat Community favor NEOS or SLS? Neos Therapeutics received 490 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 63.78% of users gave Neos Therapeutics an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformNeos TherapeuticsOutperform Votes50063.78% Underperform Votes28436.22% SELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% SummaryNeos Therapeutics beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.35M$6.59B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-1.706.7882.8815.55Price / Sales82.34357.041,246.7687.28Price / CashN/A53.8240.9136.92Price / Book5.0910.617.206.55Net Income-$37.34M$153.27M$119.63M$226.22M7 Day Performance-11.36%3.97%2.12%3.77%1 Month Performance4.46%-6.72%-2.43%4.64%1 Year Performance15.84%33.26%34.53%29.21% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group0.0759 of 5 stars$1.17-4.1%N/A+17.0%$82.35M$1M-1.7016NEOSNeos TherapeuticsN/A$1.15flatN/A+0.0%$57.22M$64.65M-3.38213High Trading VolumeCORVCorrevio PharmaN/A$0.42flatN/AN/A$27.80M$32.63M-0.53133KMDAKamada3.8064 of 5 stars$5.85+0.5%$14.50+147.9%+23.6%$336.26M$142.52M20.89360BTMDbiote3.0299 of 5 stars$6.14+1.3%$8.39+36.6%+15.9%$332.91M$185.36M23.31194QTTBQ32 Bio1.6232 of 5 stars$27.04-0.9%$72.33+167.5%N/A$329.35M$1.16M0.0039High Trading VolumeJSPRJasper Therapeutics2.4897 of 5 stars$21.84+4.1%$74.86+242.8%+254.2%$327.60MN/A-4.6120ACIUAC Immune2.3422 of 5 stars$3.29+1.5%$12.00+264.7%+11.9%$325.51M$16.48M-7.07140Positive NewsCYRXCryoport2.8781 of 5 stars$6.58+0.2%$12.50+90.1%-53.2%$325.01M$233.26M-1.951,170Insider TradeDSGNDesign Therapeutics0.6744 of 5 stars$5.56+1.5%$7.00+25.9%+154.3%$314.79MN/A0.0040KODKodiak Sciences3.0078 of 5 stars$5.90+1.9%$3.50-40.7%+157.9%$310.46MN/A0.0090 Related Companies and Tools Related Companies Neos Therapeutics Alternatives Correvio Pharma Alternatives Kamada Alternatives biote Alternatives Q32 Bio Alternatives Jasper Therapeutics Alternatives AC Immune Alternatives Cryoport Alternatives Design Therapeutics Alternatives Kodiak Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLS Stock Alerts